Results 51 to 60 of about 16,304 (256)

Techno‐Economic Analysis of Membrane‐Based Purification Platforms for AAV Vector Production

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Technologies for large‐scale manufacturing of viral vectors for gene therapies, such as tangential flow filtration and membrane chromatography, are under development. In these early stages of process development, techno‐economic analyses are useful for identifying membrane properties yielding the greatest impact on process performance. In this
Juan J. Romero, Eleanor W. Jenkins, Jacob I. Monroe, S. Ranil Wickramasinghe, Xianghong Qian, Dibakar Bhattacharyya, Scott M. Husson   +6 more
wiley   +1 more source

Anti-TNFα in inflammatory bowel disease: from originators to biosimilars

Frontiers in Pharmacology
The introduction of anti-tumor necrosis factor α (TNFα) biologics significantly innovated inflammatory bowel disease (IBD) treatment and increased medical costs.
Zhen Zeng, Zhen Zeng, Zhen Zeng, Hao Lin, Hao Lin, Hao Lin, Mingshan Jiang, Mingshan Jiang, Mingshan Jiang, Jing Yuan, Jing Yuan, Jing Yuan, Xi Li, Xi Li, Yongbin Jia, Li Yang, Hu Zhang, Hu Zhang, Hu Zhang   +18 more
doaj   +1 more source

The Daring of Biosimilars

Archives of Biotechnology and Biomedicine, 2017
The so-called “biotechnological revolution” is changing the structure of the Pharmacopoeia [1]. The space of biological products, previously limited to blood products and vaccines, grew from the introduction of first recombinant therapeutics in the 1980s until attaining a 25% by value of the pharmaceutical market. This share is expected to reach 50% in
Nuris Ledón, Agustin Lage
openaire   +2 more sources

A Surface Plasmon Resonance‐Based Integrated Assay for Quantification and Glycosylation Characterization of Monoclonal Antibodies in Crude Heterogeneous Samples

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The rise in cancer, autoimmune, inflammatory, and infectious diseases in recent decades has led to a surge in the development of monoclonal antibodies (mAbs) therapies, now the most widely used family of biologics. To meet the growing global demand, biopharmaceutical industries are intensifying their production processes.
Ilona Metayer, Catherine Forest‐Nault, Julie Guimond, Simon Joubert, Olivier Henry, Yves Durocher, Gregory De Crescenzo, Jimmy Gaudreault   +7 more
wiley   +1 more source

Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis

Frontiers in Pharmacology, 2022
Background: The level of competition achieved following biosimilars market availability varies by country, care setting and molecule. Hence, biosimilars contribution to attaining price reductions and extended access to treatments can also vary.Objective:
Teresa Barcina Lacosta, Arnold G. Vulto, Arnold G. Vulto, Isabelle Huys, Steven Simoens   +4 more
doaj   +1 more source

Techno‐economic analysis of membrane‐based continuous capture chromatography platforms for large‐scale antibody production

Biotechnology Progress, EarlyView.
Abstract Continuous manufacturing platforms and membrane chromatography are process technologies with the potential to reduce production costs and minimize process variability in monoclonal antibody production. This study presents a simulation and optimization framework to perform techno‐economic analyses of these strategies.
Juan J. Romero, Eleanor W. Jenkins, Marc R. Birtwistle, Scott M. Husson   +3 more
wiley   +1 more source

Knowledge and attitudes of German and Swiss community pharmacists towards biologicals and biosimilars – a prospective survey before and after the COVID-19 pandemic

BMC Health Services Research, 2023
Background Knowledge, attitudes and substitution laws of biosimilars are not consistent across countries. Biosimilar acceptance among patients and healthcare professionals may be suffering from gaps in knowledge and understanding about biosimilars and ...
Kirstin Messner, Christiane Eickhoff, Martin Schulz, Samuel S. Allemann, Isabelle Arnet   +4 more
doaj   +1 more source

Optimization of multi‐column chromatography for capture and polishing at high protein load

Biotechnology Progress, EarlyView.
Abstract Integrated Continuous Biomanufacturing reduces manufacturing costs while maintaining product quality. A key contributor to high biopharmaceutical costs, specifically monoclonal antibodies (mAbs), is chromatography. Protein A ligands are usually preferred but still expensive in the manufacturing context, and batch chromatography under‐utilizes ...
Tiago Castanheira Silva, Madelène Isaksson, Bernt Nilsson, Michel Eppink, Marcel Ottens   +4 more
wiley   +1 more source

Safety of switching between rituximab biosimilars in onco-hematology

Scientific Reports, 2021
Comparable clinical efficacy and safety of the reference rituximab (MABTHERA) and its biosimilars has been established in randomized trials. However, safety concerns are often raised when switching from reference to biosimilar products and between ...
Silvana A. M. Urru, Stefania Spila Alegiani, Anna Guella, Giuseppe Traversa, Annalisa Campomori   +4 more
doaj   +1 more source

Biosimilars: New guns for the treatment of rheumatological patients? [PDF]

Beyond Rheumatology, 2019
The advent of biological therapies in 2000s has represented a real revolution in the treatment of patients affected by rheumatic diseases, but biosimilars represent nowadays a further revolution both from an economic point of view and for the ...
Daniela Marotto, Angela Ceribelli, Piercarlo Sarzi Puttini   +2 more
doaj   +1 more source